Neurology Alert – August 1, 2025

Long-Term Peripheral Nerve Function Changes in People with Well-Controlled Type 2 Diabetes

The authors conducted a prospective observational study comparing the effect of early diagnosed, well-controlled type 2 diabetes on peripheral nerve function. Overall, they found similar rates of decline in nerve function in people with well-controlled diabetes compared to age- and sex-matched individuals with normal glucose tolerance. Given the similar decline in nerve function, the authors concluded that the course of diabetic sensorimotor neuropathy is influenced primarily by nerve function at the time of diagnosis and age-related physiological decline.

CSF α-Synuclein Seed Amplification Assays in Parkinsonian Syndromes

This large longitudinal study, which looked at cerebrospinal fluid α-synuclein seed amplification assays (SAAs) from three large cohorts, demonstrated efficacy in distinguishing between Parkinson’s disease and progressive supranuclear palsy, as well as predicting cognitive decline based on kinematic analysis of the SAA samples.

Tolebrutinib May Slow Disability Progression in Patients with SPMS

A recent prospective study showed that tolebrutinib slows disability progression in patients with nonrelapsing secondary progressive multiple sclerosis (SPMS). There were some safety concerns, especially hepatotoxicity. A lack of demonstrated effect on some functional outcomes warrants careful consideration and continuing study.

Blood GFAP Measurements for Rapid Diagnosis of ICH

The early diagnosis of spontaneous intracerebral hemorrhage (ICH) is important to initiate rapid interventions, such as lowering blood pressure and reversing the effects of antithrombotic medications. Plasma assays of glial fibrillary acidic protein may become a useful tool for the prehospital diagnosis of ICH, but it needs further study before adoption in the clinical setting.